News

Tempus AI’s Personalis deal puts acquisition price and growth bets in focus Tempus AI (TEM) has moved to acquire cancer testing company Personalis in a roughly $1.5 billion all stock deal, immediately putting the spotlight on valuation, integration risk, and long term growth assumptions. The agreement would fold Personalis’ minimal residual disease, or MRD, testing into Tempus AI’s precision oncology and data platform. The combined business would target a cancer monitoring market estimated at...

The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test

Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.

Tempus AI (NasdaqGS:TEM) agreed to acquire cancer monitoring company Personalis in a deal valued at about US$1.5b. The transaction is focused on expanding Tempus AI's presence in minimal residual disease (MRD) testing and precision oncology. The company plans to combine Personalis' MRD technology with its existing AI driven precision oncology platform. For investors following Tempus AI, this deal highlights how central MRD testing and precision oncology have become in cancer care. Tempus AI...

Tempus AI stock has fallen 22.4% year to date, yet the valuation checks paint a mixed picture rather than a clear bargain or clear overvaluation. This puts the recent share price weakness under scrutiny. Year to date, Tempus AI is down 22.4%, a move that raises the question of whether sentiment has swung too far relative to the company’s fundamentals. On the positive side, progress in deploying its prostate cancer AI tools in real clinical settings can support expectations for future...

Tempus will pay a 5.6% premium to integrate Personalis' cancer-testing platform into its AI-enabled oncology business.

The brokerage said the acquisition strengthens Tempus AI’s precision oncology business, though near-term financials are less compelling.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

Tempus AI (TEM) agreed to acquire cancer test maker Personalis (PSNL) in a $1.5 billion deal that Ne

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou

Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.

Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a...

Tempus AI is acquiring Personalis to accelerate the development and commercialization of cancer-monitoring solutions.

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Tempus AI (TEM) has agreed to acquire Personalis (PSNL) in a deal with a total enterprise value of $

Personalis stock popped Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Editor’s Note: This story has been updated to correct details related to Intel (INTC). When it comes to tracking the trading activity of members of Congress, former Speaker of the House Nancy Pelosi (D-Calif.) has been among the most followed....

Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best Under-the-Radar Stocks to Invest In. On July 1, Freedom Capital initiated coverage of Tempus AI, Inc. (NASDAQ:TEM) with a Hold rating. The firm gave a $59 price target on the shares. In an investor note, the firm noted that healthcare AI remains one of the […]

Tempus AI Inc. (NASDAQ:TEM) is one of the top 10 hidden AI stocks to buy. On May 31, Tempus AI launched the next generation of Lens, an agentic AI platform designed to accelerate oncology drug development. By integrating Tempus’ massive library of longitudinal real-world data, oncology foundation models, and computational infrastructure, the platform provides an […]

Tempus AI Inc. (NASDAQ:TEM) is one of BlackRock’s 30 most important AI stocks right now. BlackRock holds a 5.14% stake in the company, with 8.97 million shares as of March 31, 2026. However, Cathie Wood’s ARK Investment Management controls a slightly higher stake at 5.51%, making BlackRock the second-largest institutional holder. Tempus became an investor […]

By Karen Roman CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which includes its leading product, NavDx, a blood-based test for viral-mediated cancer detection including human papillomavirus, and associated head and neck and anal cancers. NavDx is the first and only Medicare-covered test for HPV-driven head and neck and anal cancer molecular […] The post CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology appeared first on ExecEdge.

Tempus AI stock has jumped 18.6% over the past week, yet the valuation picture is mixed, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the broader checks suggest the shares are not a clear bargain. The 18.6% gain in the past week signals that expectations around Tempus AI have been reset quickly. This can leave new buyers with less room for error if sentiment cools. Strong revenue growth and expanding data and AI partnerships can support long...

Tempus AI recently announced a research collaboration with Angiosarcoma Awareness, Inc. to apply its approximately 600 de-identified, molecularly sequenced angiosarcoma records and analytical resources to deepen understanding of this rare and aggressive cancer. This partnership creates one of the largest known angiosarcoma molecular datasets, offering researchers a more comprehensive view of disease biology and potential therapeutic opportunities that are hard to see in smaller, fragmented...

Freedom Capital initiated Tempus AI with a Hold rating and $59 price target, saying valuation looks “about right.

The biggest long-term winners of the AI revolution may be the companies supplying the compute, power, cooling, deployment, and data infrastructure that every AI model depends on.

Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

Congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.) is one of the most followed members of Congress when it comes to her disclosed stock and options trades. Here’s a look at the trades disclosed by Pelosi since the...